Company Overview
| Stock Name | 朗生醫藥控股有限公司 |
|---|---|
| Stock Code | 00503 |
| Company Full Name | 朗生醫藥控股有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 主要在中國從事開發、生產及銷售治療風濕免疫疾病的專科處方西藥，亦生產及銷售其他藥品。 |
| Listing Date | 2010-05-07 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港德輔道中189號李寶樁大廈12樓1203-4室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.lansen.com.cn |
| Share Registrar | |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 3.91 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 276,339,250 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 4.56 |
|---|---|
| First Day Open | HK$ 4.8 |
| First Day Change | 16.62% |
| First Day Volume | 194428000.0 |
| First Day Turnover | 942005000.0 |
Use of Proceeds
| Use of Proceeds | 1、約91.4百萬港元，將撥支作產品開發及研究； 2、約106.6百萬港元，將撥支作收購及╱或購買生產技術或新藥物的已授出批文的權利； 3、約39.6百萬港元，將撥支作擴充原料生產設施； 4、約39.6百萬港元，將用作增加我們的核心產品的醫院覆蓋率至一至三級醫院； 5、約27.3百萬港元，用作一般營運資金用途。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
Piper Jaffray Asia Limited CE AEG682
Joint Bookrunners (1)
PIPER JAFFRAY ASIA SECURITIES LIMITED CE ABO154
Joint Lead Managers (1)
PIPER JAFFRAY ASIA SECURITIES LIMITED CE ABO154
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Chairman | 吳鎮濤 |
|---|---|
| Company Secretary | 彭啟輝 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 吳鎮濤(67.62%) |
|---|
